This website uses cookies

Read our Privacy policy and Terms of use for more information.

Weight loss drugs like Wegovy and Zepbound have changed what's possible for people struggling with obesity. But even as these medications help more people lose weight, experts say there's a bigger problem they can't solve: a world where eating well isn't always easy, affordable or convenient.

A new report published in JAMA brings together more than 50 experts to examine why obesity has become so widespread and what it will take to address it. Their conclusion is that medication can play an important role, but lasting progress also depends on improving access to nutritious food, making healthier choices easier and providing better long-term care.

The report draws on existing research and discussions among experts in nutrition, medicine, public health and industry, rather than presenting results from a new study. Several contributors also disclosed financial ties to companies that make obesity medications.

Consider how much American eating habits have changed over the past several decades. Portions have grown, inexpensive convenience foods are widely available and food advertising is nearly impossible to escape. Meanwhile, busy schedules leave many people with less time to shop for ingredients and prepare meals at home.

The report also examines ultraprocessed foods, which make up roughly 55% of the American diet. While some research links these foods to weight gain, the authors acknowledge that evidence about their role in the overall rise in obesity is mixed. Not all processed foods are nutritionally alike, and processing alone doesn't determine whether a food is healthy.

These challenges can be especially difficult for people with limited time or money. Fresh produce and other nutritious options may be harder to find or afford, while demanding work schedules and family responsibilities can make cooking regularly unrealistic.

And even when someone makes changes and loses weight, keeping it off isn't necessarily straightforward. The body can respond to weight loss by making a person feel hungrier and burning fewer calories, creating an uphill battle that willpower alone may not overcome.

That's one reason newer weight loss medications have attracted so much attention. They can help reduce hunger and make it easier for some people to lose substantial amounts of weight. But they aren't right for everyone, and cost, side effects and the possibility of needing treatment for years can make them difficult to use or maintain.

The experts argue that improving obesity prevention and care means looking beyond medications. That includes helping families afford nutritious groceries, improving school meals, making nutrition education more accessible and ensuring people have support when they're trying to make lasting changes.

Some approaches have shown promise. Programs that make fruits and vegetables more affordable, for example, have helped people purchase and eat more of them, although it's less clear whether those changes lead to lasting reductions in obesity. Other efforts, such as nutrition labels and taxes on sugary drinks, have produced mixed or modest results.

The report also calls attention to weight stigma. People living with obesity often encounter judgment about their appearance or assumptions that they simply lack discipline. Those attitudes can discourage people from seeking care and make an already difficult health challenge even harder.

Ultimately, the authors argue that obesity treatment and prevention shouldn't be treated as separate problems. Medications may help individuals manage their weight, but they can't change what's available at the grocery store, how foods are marketed or whether families can afford nutritious meals.

As the researchers write, "If the food environment is not addressed, gains will be minimal."

The American Medical Association Foundation supported the 2026 JAMA Summit on Obesity. Several report contributors disclosed financial relationships with pharmaceutical companies, including Novo Nordisk and Eli Lilly, as well as other food and health-related businesses. The report reflects a review of existing evidence and expert recommendations, not findings from a new clinical trial.